PROCEPT BioRobotics Reports Strong 37% Revenue Growth, Improved Margins, and Key Reimbursement Upgrade in 2025 Annual Report

summarizeSummary

PROCEPT BioRobotics reported strong 37% revenue growth and improved gross margins for fiscal year 2025, alongside a significant upgrade to a Category I CPT code for its Aquablation therapy, enhancing future reimbursement prospects despite continued net losses.

check_boxKey Events

• Strong Full-Year Revenue Growth

  The company reported $308.1 million in revenue for fiscal year 2025, representing a substantial 37% increase compared to $224.5 million in 2024.

• Improved Gross Margin

  Gross margin increased to 64% in 2025, up from 61% in 2024, indicating enhanced operational efficiency and scale.

• Continued Net Losses

  PROCEPT BioRobotics incurred a net loss of $95.6 million in 2025, a slight increase from $91.4 million in 2024, as the company continues to invest in growth and development.

• Significant Reimbursement Upgrade

  Aquablation therapy was assigned a new Category I CPT code (52597), effective January 1, 2026, replacing the prior Category III code. This is a major positive for future reimbursement and broader market acceptance.

auto_awesomeAnalysis

PROCEPT BioRobotics' 2025 annual report confirms robust operational performance with significant revenue growth and improved gross margins. The upgrade of Aquablation therapy to a Category I CPT code, effective January 1, 2026, is a critical development that is expected to substantially enhance future reimbursement and market adoption. While the company continues to incur net losses, this is typical for a growth-stage medical technology firm, and the reported liquidity provides sufficient runway for the next 12 months. This filing provides the audited details following the preliminary Q4 and full-year results likely announced in a recent 8-K, and reinforces the strategic direction discussed at the Investor Day.